Results 181 to 190 of about 22,886 (216)

Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART. [PDF]

South Afr J HIV Med
Naidoo K, Lessells RJ, Dorward J, Moosa MYS, Sookrajh Y, Moodley P, Drain PK, Garrett N.   +7 more
europepmc   +1 more source

Dolutegravir/Abacavir/Lamivudine in Acute HIV-1 Results in Rapid Suppression and Restoration of CD4 T-cell Subsets Without Accelerated Decay of Latent HIV-1. [PDF]

Open Forum Infect Dis
Gay CL, Keys J, Kuruc JD, Sponaugle A, McGee KS, Ang C, Baker CE, Weimer ET, Schmitz JL, Archin NM, McKellar MS, Goonetilleke N, Margolis DM, Eron JJ.   +13 more
europepmc   +1 more source

High concordance of human immunodeficiency virus-1 genotypic drug resistance generated from paired cerebrospinal fluid and plasma in antiretroviral therapy -naive or -experienced patients. [PDF]

Front Microbiol
Deng X, Li J, He R, Wen Y, Lin Y, Li L, Ling X, Hu F, Li L, Lan Y.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Resistance to HIV integrase inhibitors

Current Opinion in HIV and AIDS, 2012
HIV integrase inhibitors are potent antiretroviral drugs that efficiently decrease viral load in patients. Emergence of resistance mutations against this new class of drugs represents a threat to their long-term efficacy. The purpose of this review is to provide new information about the most recent mutations identified and other mutations that confer ...
Peter K. Quashie, Mark A. Wainberg, Thibault Mesplède   +2 more
openaire   +6 more sources

Novel integrase inhibitors for HIV

Expert Opinion on Investigational Drugs, 2010
Integrase inhibitors are the newest class of antiretroviral agents developed to treat HIV-1 infection. Raltegravir (RAL), the only integrase inhibitor (INI) currently approved for the treatment of HIV-infected patients, has proven to be a potent and well-tolerated antiretroviral (ARV) agent.
Martin Markowitz, Nicole Prada
openaire   +3 more sources

Tolerability of HIV integrase inhibitors

Current Opinion in HIV and AIDS, 2012
This review discusses the available safety data for three integrase strand transfer inhibitors (INSTIs)--raltegravir, elvitegravir and dolutegravir--derived from studies in both HIV-infected and HIV-uninfected cohorts.Phase 2 and 3 clinical trials show that all three INSTIs are well tolerated in treatment-naive and treatment-experienced patients with ...
Frederick J. Lee, Andrew Carr
openaire   +2 more sources